Anzeige
Mehr »
Sonntag, 06.07.2025 - Börsentäglich über 12.000 News
LiquidLink startet Bitcoin Lightning- und XRP-ILP-Nodes - Aufbau des Rückgrats der tokenisierten Finanzwelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
851 Leser
Artikel bewerten:
(2)

Veeva Systems: Dr. Pfleger Arzneimittel Scales Digital Field Engagement with Veeva Commercial Cloud

Mid-sized pharmaceutical company sets digital foundation to drive more effective and precise engagement

BARCELONA, Spain, Feb. 27, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that mid-sized pharmaceutical company Dr.Pfleger Arzneimittel GmbH has selected Veeva Commercial Cloud, including Veeva CRM and Veeva CLM, alongside Veeva OpenData. With Veeva Commercial Cloud, Dr.Pfleger's field team can lead more effective field engagement in Germany and Austria, reaching the right healthcare professionals (HCPs) with timely, relevant content.

Veeva Systems

"Veeva is an important partner for us, with its deep industry expertise and consistent innovation to help our field team work more digitally and efficiently," says Dr. Günter Auerbach, managing director at Dr. Pfleger. "With Veeva Commercial Cloud and Veeva OpenData, we have the foundation for a single source of truth for HCP relationships," added Ralf Will, managing director at Dr. Pfleger.

Located in Bamberg, Germany with over 400 employees, Dr. Pfleger specializes in developing, manufacturing, and distributing pharmaceuticals and medical products, including prescription medicines across (Rx) urology and gynecology, as well as over-the-counter medicines, like well-known brands ipalat® and BIO-H-TIN®. Veeva CRM provides Dr. Pfleger with important functions for creating customer profiles, territory and account planning, and documenting field service visits. Combined with Veeva CLM and Veeva OpenData, Dr. Pfleger can manage interactive content with insights into what resonates most with customers and access a comprehensive customer reference database for a complete picture of the healthcare ecosystem.

"As Dr.Pfleger continues to grow its products and field team in Europe, it needs connected digital solutions to drive impactful conversations with customers," says Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. "By opting for Veeva Commercial Cloud with Veeva OpenData, Dr. Pfleger is setting the foundation for commercial excellence as it expands."

Veeva CRM and Veeva CLM are part of Veeva Commercial Cloud, the technology foundation for commercial innovation in life sciences. Veeva OpenData is part of Veeva Data Cloud, the modern data platform for life sciences that connects commercial and clinical for greater precision and speed.

Additional Information
For more on Veeva Commercial Cloud, visit: veeva.com/eu/Commercial Cloud Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:


Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com


Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/dr-pfleger-arzneimittel-scales-digital-field-engagement-with-veeva-commercial-cloud-302072416.html

© 2024 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.